[
  {"id":"B02-20160301-001","en":"ANDS (Abbreviated New Drug Submission)","fr":"ANDS (Présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-031","en":"EU NDS (Extraordinary Use New Drug Submission)","fr":"EU NDS (Présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-032","en":"EUSNDS (Extraordinary Use Supplement to a New Drug Submission)","fr":"EUSNDS (Supplément à une présentation de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20160301-038","en":"Level 3 – Notice of Change","fr":"Niveau 3 - Déclaration de changements"},
  {"id":"B02-20160301-046","en":"MPNC (Pre-Submission Meeting Information)","fr":"MPNC (Réunion préalable - PM)"},
  {"id":"B02-20160301-047","en":"MPNDS (Pre-Submission Meeting Information)","fr":"MPNDS (Réunion préalable – PDN)"},
  {"id":"B02-20160301-049","en":"MPSNDS (Pre-Submission Meeting Information)","fr":"MPSNDS (Réunion préalable – RPPDN)"},
  {"id":"B02-20160301-050","en":"NC (Notifiable Change)","fr":"NC (Préavis de modification)"},
  {"id":"B02-20160301-051","en":"NDS (New Drug Submission)","fr":"NDS (Présentation de drogue nouvelle)"},
  {"id":"B02-20160301-067","en":"PAND (Pandemic Application)","fr":"PAND (Demande pandémique)"},
  {"id":"B02-20160301-068","en":"PBRER-C (Periodic Benefit Risk Evaluation Report - Confirmatory)","fr":"PBRER-C (Rapport périodique d'évaluation des avantages et des risques - confirmation)"},
  {"id":"B02-20160301-069","en":"PBRER-PV (Periodic Benefit Risk Evaluation Report - Post-market Vigiliance)","fr":"PBRER-PV (rapport périodique d'évaluation des avantages et des risques - Vigilance après la mise en marché)"},
  {"id":"B02-20160301-075","en":"PRNDS (Request for Priority Review Status: NDS)","fr":"PRNDS (Demande de statut d’évaluation prioritaire - PDN)"},
  {"id":"B02-20160301-077","en":"PRSNDS (Request for Priority Review Status: SNDS)","fr":"PRSNDS (Demande de statut d’évaluation prioritaire - SPDN)"},
  {"id":"B02-20160301-078","en":"PSUR-C (Periodic Safety Update Report - Confirmatory)","fr":"PSUR-C (Rapport périodique de pharmacovigilance - Confirmation)"},
  {"id":"B02-20160301-079","en":"PSUR-PV (Periodic Safety Update Report - Post-Market Vigilance)","fr":"PSUR-PV (Rapport périodique de pharmacovigilance - pharmacovigilance)"},
  {"id":"B02-20160301-080","en":"RMP-PV (Risk Management Plan - Post-Market Vigilance)","fr":"RMP-PV (Plan de gestion des risques - Pharmacovigilance)"},
  {"id":"B02-20160301-082","en":"SANDS (Supplement to an Abbreviated New Drug Submission)","fr":"SANDS (Supplément à une présentation abrégée de drogue nouvelle)"},
  {"id":"B02-20160301-084","en":"SNDS (Supplement to a New Drug Submission)","fr":"SNDS (Supplément à une présentation de drogue nouvelle)"},
  {"id":"B02-20160301-085","en":"SNDS-C (Supplement to a New Drug Submission - Confirmatory)","fr":"SNDS-C (Supplément à 'une présentation de drogue nouvelle - Confirmation)"},
  {"id":"B02-20160301-088","en":"UDRA (Undefined Regulatory Activity)","fr":"UDRA (Activité réglementaire non définie)"},
  {"id":"B02-20160301-089","en":"YBPR (Yearly Biologic Product Report)","fr":"YBPR (Rapport annuel sur un produit biologique)"},
  {"id":"B02-20160301-028","en":"DSUR (Developmental Safety Update Report)","fr":"DSUR (Rapports de mises à jour aux produits en développement)"},
  {"id":"B02-20160301-018","en":"DINA (Application for Drug Identification Number)","fr":"DINA (Demande d'identification numérique de drogue)"},
  {"id":"B02-20160301-019","en":"DINB (Application for Drug Identification Number - Biologic)","fr":"DINB (Demande d'identification numérique de drogue - produits biologiques)"},
  {"id":"B02-20160301-020","en":"DIND (Application for Drug Identification Number - Disinfectant Product)","fr":"DIND (Demande d'identification numérique de drogue - produits désinfectant)"},
  {"id":"B02-20160301-021","en":"DINF (Application for Drug Identification Number - Category IV Product)","fr":"DINF (Demande d'identification numérique de drogue - produits catégorie IV)"},
  {"id":"B02-20160301-043","en":"MPDIN (Pre-Submission Meeting Information)","fr":"MPDIN (Information des rencontres préalables à la présentation)"},
  {"id":"B02-20160301-070","en":"PDC (Post-Authorization Division 1 Change)","fr":"PDC (Changement post-approbation de Titre 1)"},
  {"id":"B02-20160301-071","en":"PDC-B (Post-Authorization Division 1 Change - Biologics)","fr":"PDCB (Changement post-approbation de Titre 1 - biologiques)"},
  {"id":"B02-20190627-01","en":"IRSRPV (Issue Related Summary Report - Post-market Vigilance)","fr":"IRSRPV (Rapport de synthèse relatif à un sujet de préoccupation)"},
  {"id":"B02-20190627-02","en":"PA-PV (Post-Authorization commitments - Post-market Vigilance)","fr":"PA-PV (Engagements postérieurs à l'autorisation - Vigilance après la commercialisation)"},
  {"id":"B02-20190627-03","en":"PSA-PV (Patient Safety/Advertising Ad-Hoc Post market requests - Post-market Vigilance)","fr":"PSA-PV (Demandes postérieures à la commercialisation sur la sécurité des patients/la publicité ad hoc)"},
  {"id":"B02-20190627-04","en":"RC-PV (Risk Communication - Post-market Vigilance)","fr":"RC-PV (Rapport de synthèse relatif à un sujet de préoccupation)"},
  {"id":"B02-20190627-05","en":"REG-PV (Post-Authorization Act and Regulations - Post-market Vigilance)","fr":"REG-PV (Loi et règlements postérieurs à l'autorisation - Vigilance après la commercialisation)"},
  {"id":"B02-20190627-06","en":"SANDS-C (Supplement to a New Abbreviated Drug Submission - Confirmatory","fr":"SANDS-C (Supplément à une présentation abrégée de drogue nouvelle - Confirmation)"},
  {"id":"B02-20160819-01","en":"Post-DIN Notification","fr":"Avis après la délivrance d'un DIN "},
  {"id":"B02-20190627-07","en":"EUANDS (Extraordinary Use Abbreviated New Drug Submission)","fr":"EUANDS (Présentation abrégée de drogue nouvelle pour usage exceptionnel)"},
  {"id":"B02-20190627-08","en":"EUSANDS (Extraordinary Use Supplement to a Abbreviated New Drug Submission)","fr":"EUSANDS (Supplément à une présentation abrégée de drogue nouvelle pour usage exceptionnel)"}
]

